Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China
Background: Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma with high mortality and poor prognosis despite radiotherapy and chemotherapy. The current analysis aimed to assess the pathological features, clinical features, and prognostic indicators o...
Gespeichert in:
Veröffentlicht in: | Oncology research and treatment 2016-01, Vol.39 (1-2), p.45-52 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 52 |
---|---|
container_issue | 1-2 |
container_start_page | 45 |
container_title | Oncology research and treatment |
container_volume | 39 |
creator | Liang, Rong Wang, Zhe Bai, Qing-Xian Gao, Guang-Xun Yang, Lan Zhang, Tao Gu, Hong-Tao Dong, Bao-Xia Shu, Mi-Mi Hao, Cai-Xia Zhang, Na Chen, Xie-Qun |
description | Background: Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma with high mortality and poor prognosis despite radiotherapy and chemotherapy. The current analysis aimed to assess the pathological features, clinical features, and prognostic indicators of ENKTL. Material and Methods: 120 ENKTL patients were analyzed for pathologic diagnosis and clinical disease manifestations from April 2007 to October 2012. Complete remission, 2-year overall survival, and progression-free survival were analyzed. Results: Compared with the nasal group, a greater percentage of patients in the non-nasal group intended to receive autologous stem cell transplantation had Epstein-Barr virus (EBV) DNA, Ann Arbor stage IV, Ki-67 expression ≥ 60%, and abnormal ferroprotein and β-microglobulin levels. The rate of complete remission in the non-nasal group was higher than that in the nasal group. The overall survival rate was 74.9% at 24 months. Patients receiving chemotherapy and radiotherapy were more likely to have disease progression compared with patients who received chemotherapy or radiotherapy alone. Conclusions: Further understanding the pathological and clinical features of ENKTL will be critical for moving forward. Ki-67, β-microglobulin, EBV DNA, and primary site prognostic indicators may be useful to stratify patients into different risk groups, to gain insight into patient-specific treatments, and to potentially improve survival. |
doi_str_mv | 10.1159/000442763 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_26891121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1767077915</sourcerecordid><originalsourceid>FETCH-LOGICAL-c306t-7b562b0711c4735d5aae11a894f649246b3e84c8d53449b942994faa44f8e2113</originalsourceid><addsrcrecordid>eNo9kN1LwzAUxYMoTuYefBfJo4J1SZqPxrdR_MIxQSY-lrRNXTT9MGmF_vdGNvd0L5zfPdxzADjD6AZjJucIIUqJ4PEBOCFE8ogRTg73u0ATMPP-M2CYMJYIeQwmhCcSY4JPQLlS_eCUhc_GWu3ma5hqa-FyrLtNW6truFI-qOux07dwAV9171rf6aI3Pxqm1jSmCPKiUXb0xkPTwFXr-k30rn2vXQPTjWnUKTiqlPV6tptT8HZ_t04fo-XLw1O6WEZFjHgfiZxxkiOBcUFFzEqmlMZYJZJWnEpCeR7rhBZJyWJKZS4pkUFSitIq0QTjeAout76da7-H8EFWG1-EPKrR7eAzLLhAQkjMAnq1RYuQxztdZZ0ztXJjhlH212u27zWwFzvbIa91uSf_WwzA-Rb4Uu5Duz2wu_8FI9x5MA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1767077915</pqid></control><display><type>article</type><title>Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Liang, Rong ; Wang, Zhe ; Bai, Qing-Xian ; Gao, Guang-Xun ; Yang, Lan ; Zhang, Tao ; Gu, Hong-Tao ; Dong, Bao-Xia ; Shu, Mi-Mi ; Hao, Cai-Xia ; Zhang, Na ; Chen, Xie-Qun</creator><creatorcontrib>Liang, Rong ; Wang, Zhe ; Bai, Qing-Xian ; Gao, Guang-Xun ; Yang, Lan ; Zhang, Tao ; Gu, Hong-Tao ; Dong, Bao-Xia ; Shu, Mi-Mi ; Hao, Cai-Xia ; Zhang, Na ; Chen, Xie-Qun</creatorcontrib><description>Background: Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma with high mortality and poor prognosis despite radiotherapy and chemotherapy. The current analysis aimed to assess the pathological features, clinical features, and prognostic indicators of ENKTL. Material and Methods: 120 ENKTL patients were analyzed for pathologic diagnosis and clinical disease manifestations from April 2007 to October 2012. Complete remission, 2-year overall survival, and progression-free survival were analyzed. Results: Compared with the nasal group, a greater percentage of patients in the non-nasal group intended to receive autologous stem cell transplantation had Epstein-Barr virus (EBV) DNA, Ann Arbor stage IV, Ki-67 expression ≥ 60%, and abnormal ferroprotein and β-microglobulin levels. The rate of complete remission in the non-nasal group was higher than that in the nasal group. The overall survival rate was 74.9% at 24 months. Patients receiving chemotherapy and radiotherapy were more likely to have disease progression compared with patients who received chemotherapy or radiotherapy alone. Conclusions: Further understanding the pathological and clinical features of ENKTL will be critical for moving forward. Ki-67, β-microglobulin, EBV DNA, and primary site prognostic indicators may be useful to stratify patients into different risk groups, to gain insight into patient-specific treatments, and to potentially improve survival.</description><identifier>ISSN: 2296-5270</identifier><identifier>EISSN: 2296-5262</identifier><identifier>DOI: 10.1159/000442763</identifier><identifier>PMID: 26891121</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Adolescent ; Adult ; Age Distribution ; Aged ; Aged, 80 and over ; Chemoradiotherapy - mortality ; Chemoradiotherapy - statistics & numerical data ; Child ; China - epidemiology ; Disease-Free Survival ; Female ; Humans ; Lymphoma, Extranodal NK-T-Cell - diagnosis ; Lymphoma, Extranodal NK-T-Cell - mortality ; Lymphoma, Extranodal NK-T-Cell - therapy ; Male ; Middle Aged ; Nose Neoplasms - diagnosis ; Nose Neoplasms - mortality ; Nose Neoplasms - therapy ; Original Article ; Prevalence ; Retrospective Studies ; Risk Factors ; Sex Distribution ; Survival Rate ; Young Adult</subject><ispartof>Oncology research and treatment, 2016-01, Vol.39 (1-2), p.45-52</ispartof><rights>2016 S. Karger GmbH, Freiburg</rights><rights>2016 S. Karger GmbH, Freiburg.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c306t-7b562b0711c4735d5aae11a894f649246b3e84c8d53449b942994faa44f8e2113</citedby><cites>FETCH-LOGICAL-c306t-7b562b0711c4735d5aae11a894f649246b3e84c8d53449b942994faa44f8e2113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26891121$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liang, Rong</creatorcontrib><creatorcontrib>Wang, Zhe</creatorcontrib><creatorcontrib>Bai, Qing-Xian</creatorcontrib><creatorcontrib>Gao, Guang-Xun</creatorcontrib><creatorcontrib>Yang, Lan</creatorcontrib><creatorcontrib>Zhang, Tao</creatorcontrib><creatorcontrib>Gu, Hong-Tao</creatorcontrib><creatorcontrib>Dong, Bao-Xia</creatorcontrib><creatorcontrib>Shu, Mi-Mi</creatorcontrib><creatorcontrib>Hao, Cai-Xia</creatorcontrib><creatorcontrib>Zhang, Na</creatorcontrib><creatorcontrib>Chen, Xie-Qun</creatorcontrib><title>Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China</title><title>Oncology research and treatment</title><addtitle>Oncol Res Treat</addtitle><description>Background: Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma with high mortality and poor prognosis despite radiotherapy and chemotherapy. The current analysis aimed to assess the pathological features, clinical features, and prognostic indicators of ENKTL. Material and Methods: 120 ENKTL patients were analyzed for pathologic diagnosis and clinical disease manifestations from April 2007 to October 2012. Complete remission, 2-year overall survival, and progression-free survival were analyzed. Results: Compared with the nasal group, a greater percentage of patients in the non-nasal group intended to receive autologous stem cell transplantation had Epstein-Barr virus (EBV) DNA, Ann Arbor stage IV, Ki-67 expression ≥ 60%, and abnormal ferroprotein and β-microglobulin levels. The rate of complete remission in the non-nasal group was higher than that in the nasal group. The overall survival rate was 74.9% at 24 months. Patients receiving chemotherapy and radiotherapy were more likely to have disease progression compared with patients who received chemotherapy or radiotherapy alone. Conclusions: Further understanding the pathological and clinical features of ENKTL will be critical for moving forward. Ki-67, β-microglobulin, EBV DNA, and primary site prognostic indicators may be useful to stratify patients into different risk groups, to gain insight into patient-specific treatments, and to potentially improve survival.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Distribution</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Chemoradiotherapy - mortality</subject><subject>Chemoradiotherapy - statistics & numerical data</subject><subject>Child</subject><subject>China - epidemiology</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Lymphoma, Extranodal NK-T-Cell - diagnosis</subject><subject>Lymphoma, Extranodal NK-T-Cell - mortality</subject><subject>Lymphoma, Extranodal NK-T-Cell - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nose Neoplasms - diagnosis</subject><subject>Nose Neoplasms - mortality</subject><subject>Nose Neoplasms - therapy</subject><subject>Original Article</subject><subject>Prevalence</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Sex Distribution</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>2296-5270</issn><issn>2296-5262</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kN1LwzAUxYMoTuYefBfJo4J1SZqPxrdR_MIxQSY-lrRNXTT9MGmF_vdGNvd0L5zfPdxzADjD6AZjJucIIUqJ4PEBOCFE8ogRTg73u0ATMPP-M2CYMJYIeQwmhCcSY4JPQLlS_eCUhc_GWu3ma5hqa-FyrLtNW6truFI-qOux07dwAV9171rf6aI3Pxqm1jSmCPKiUXb0xkPTwFXr-k30rn2vXQPTjWnUKTiqlPV6tptT8HZ_t04fo-XLw1O6WEZFjHgfiZxxkiOBcUFFzEqmlMZYJZJWnEpCeR7rhBZJyWJKZS4pkUFSitIq0QTjeAout76da7-H8EFWG1-EPKrR7eAzLLhAQkjMAnq1RYuQxztdZZ0ztXJjhlH212u27zWwFzvbIa91uSf_WwzA-Rb4Uu5Duz2wu_8FI9x5MA</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Liang, Rong</creator><creator>Wang, Zhe</creator><creator>Bai, Qing-Xian</creator><creator>Gao, Guang-Xun</creator><creator>Yang, Lan</creator><creator>Zhang, Tao</creator><creator>Gu, Hong-Tao</creator><creator>Dong, Bao-Xia</creator><creator>Shu, Mi-Mi</creator><creator>Hao, Cai-Xia</creator><creator>Zhang, Na</creator><creator>Chen, Xie-Qun</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160101</creationdate><title>Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China</title><author>Liang, Rong ; Wang, Zhe ; Bai, Qing-Xian ; Gao, Guang-Xun ; Yang, Lan ; Zhang, Tao ; Gu, Hong-Tao ; Dong, Bao-Xia ; Shu, Mi-Mi ; Hao, Cai-Xia ; Zhang, Na ; Chen, Xie-Qun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c306t-7b562b0711c4735d5aae11a894f649246b3e84c8d53449b942994faa44f8e2113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Distribution</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Chemoradiotherapy - mortality</topic><topic>Chemoradiotherapy - statistics & numerical data</topic><topic>Child</topic><topic>China - epidemiology</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Lymphoma, Extranodal NK-T-Cell - diagnosis</topic><topic>Lymphoma, Extranodal NK-T-Cell - mortality</topic><topic>Lymphoma, Extranodal NK-T-Cell - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nose Neoplasms - diagnosis</topic><topic>Nose Neoplasms - mortality</topic><topic>Nose Neoplasms - therapy</topic><topic>Original Article</topic><topic>Prevalence</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Sex Distribution</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liang, Rong</creatorcontrib><creatorcontrib>Wang, Zhe</creatorcontrib><creatorcontrib>Bai, Qing-Xian</creatorcontrib><creatorcontrib>Gao, Guang-Xun</creatorcontrib><creatorcontrib>Yang, Lan</creatorcontrib><creatorcontrib>Zhang, Tao</creatorcontrib><creatorcontrib>Gu, Hong-Tao</creatorcontrib><creatorcontrib>Dong, Bao-Xia</creatorcontrib><creatorcontrib>Shu, Mi-Mi</creatorcontrib><creatorcontrib>Hao, Cai-Xia</creatorcontrib><creatorcontrib>Zhang, Na</creatorcontrib><creatorcontrib>Chen, Xie-Qun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liang, Rong</au><au>Wang, Zhe</au><au>Bai, Qing-Xian</au><au>Gao, Guang-Xun</au><au>Yang, Lan</au><au>Zhang, Tao</au><au>Gu, Hong-Tao</au><au>Dong, Bao-Xia</au><au>Shu, Mi-Mi</au><au>Hao, Cai-Xia</au><au>Zhang, Na</au><au>Chen, Xie-Qun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China</atitle><jtitle>Oncology research and treatment</jtitle><addtitle>Oncol Res Treat</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>39</volume><issue>1-2</issue><spage>45</spage><epage>52</epage><pages>45-52</pages><issn>2296-5270</issn><eissn>2296-5262</eissn><abstract>Background: Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma with high mortality and poor prognosis despite radiotherapy and chemotherapy. The current analysis aimed to assess the pathological features, clinical features, and prognostic indicators of ENKTL. Material and Methods: 120 ENKTL patients were analyzed for pathologic diagnosis and clinical disease manifestations from April 2007 to October 2012. Complete remission, 2-year overall survival, and progression-free survival were analyzed. Results: Compared with the nasal group, a greater percentage of patients in the non-nasal group intended to receive autologous stem cell transplantation had Epstein-Barr virus (EBV) DNA, Ann Arbor stage IV, Ki-67 expression ≥ 60%, and abnormal ferroprotein and β-microglobulin levels. The rate of complete remission in the non-nasal group was higher than that in the nasal group. The overall survival rate was 74.9% at 24 months. Patients receiving chemotherapy and radiotherapy were more likely to have disease progression compared with patients who received chemotherapy or radiotherapy alone. Conclusions: Further understanding the pathological and clinical features of ENKTL will be critical for moving forward. Ki-67, β-microglobulin, EBV DNA, and primary site prognostic indicators may be useful to stratify patients into different risk groups, to gain insight into patient-specific treatments, and to potentially improve survival.</abstract><cop>Basel, Switzerland</cop><pmid>26891121</pmid><doi>10.1159/000442763</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2296-5270 |
ispartof | Oncology research and treatment, 2016-01, Vol.39 (1-2), p.45-52 |
issn | 2296-5270 2296-5262 |
language | eng |
recordid | cdi_pubmed_primary_26891121 |
source | MEDLINE; Karger Journals; Alma/SFX Local Collection |
subjects | Adolescent Adult Age Distribution Aged Aged, 80 and over Chemoradiotherapy - mortality Chemoradiotherapy - statistics & numerical data Child China - epidemiology Disease-Free Survival Female Humans Lymphoma, Extranodal NK-T-Cell - diagnosis Lymphoma, Extranodal NK-T-Cell - mortality Lymphoma, Extranodal NK-T-Cell - therapy Male Middle Aged Nose Neoplasms - diagnosis Nose Neoplasms - mortality Nose Neoplasms - therapy Original Article Prevalence Retrospective Studies Risk Factors Sex Distribution Survival Rate Young Adult |
title | Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T21%3A20%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20Killer/T%20Cell%20Lymphoma,%20Nasal%20Type:%20A%20Retrospective%20Clinical%20Analysis%20in%20North-Western%20China&rft.jtitle=Oncology%20research%20and%20treatment&rft.au=Liang,%20Rong&rft.date=2016-01-01&rft.volume=39&rft.issue=1-2&rft.spage=45&rft.epage=52&rft.pages=45-52&rft.issn=2296-5270&rft.eissn=2296-5262&rft_id=info:doi/10.1159/000442763&rft_dat=%3Cproquest_pubme%3E1767077915%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1767077915&rft_id=info:pmid/26891121&rfr_iscdi=true |